Boardroom Alpha
Boardroom Alpha
CL · Current Report (Form 8-K) · Filed March 17, 2026

Colgate Palmolive Co — Current Report (Form 8-K)

Form
8-K
Filed
March 17, 2026
Period
Mar 17, 2026
Ticker
CL
Accession
0000021665-26-000010
Boardroom Alpha · Filing insights

Colgate realigns segments to form Europe, Middle East and Africa; Russia/Belarus moved to Asia Pacific; historical data recast.

About Colgate Palmolive Co
Market cap
$70.6B
1Y TSR
+0.9%
3Y TSR
+7.7%
Board grade
C+
Sector
Consumer Defensive
CEO
Noel R Wallace
Last annual meeting: May 8, 2026 · View full Colgate Palmolive Co profile →
cl-20260317
        
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 17, 2026

COLGATE-PALMOLIVE COMPANY
(Exact name of registrant as specified in its charter)

Delaware
1-644
13-1815595
(State or Other Jurisdiction of Incorporation)
 (Commission File Number)
(IRS Employer Identification No.)

300 Park Avenue,
New York,NY10022
 (Address of Principal Executive Offices)
(Zip Code)
                                  


Registrant’s telephone number, including area code (212) 310-2000


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Securities 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange
on which registered
Common Stock, $1.00 par value
CL
New York Stock Exchange
0.300% Notes due 2029
CL29
New York Stock Exchange
1.375% Notes due 2034
CL34
New York Stock Exchange
3.250% Notes due 2035
CL35
New York Stock Exchange
0.875% Notes due 2039
CL39
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 8.01. Other Events.

As part of the previously announced Strategic Growth and Productivity Program, to further optimize and leverage the operating scale and drive growth within the Europe and Africa/Eurasia regions, effective for the quarter ending March 31, 2026, Colgate-Palmolive Company (the “Company”) has realigned its reportable operating segments. Commencing with the Company’s financial reporting for the quarter ending March 31, 2026, the results of its Europe and Africa/Eurasia (excluding Russia and Belarus) reportable operating segments and its Skin Health business (previously within the North America reportable operating segment) will be combined to form a new Europe, Middle East and Africa reportable operating segment. In conjunction with this realignment, Russia and Belarus, which were previously reported within the Africa/Eurasia reportable operating segment, will now be reported within the Asia Pacific reportable operating segment. This reportable operating segment realignment did not impact the Company’s historical consolidated results of operations, financial position or cash flows.

For information purposes and to provide investors with historical information on a basis consistent with its new reporting structure, the Company has recast its historical geographic segment information to conform to the new reporting structure.

Attached as Exhibit 99 and incorporated by reference in this Item 8.01 are schedules containing segment information by operating segment for the years ended December 31, 2025, 2024 and 2023, the three months ended March 31, 2025, the three and six months ended June 30, 2025 and the three and nine months ended September 30, 2025.

As noted above, the segment change and supplemental disclosures discussed above have no impact on the Company’s historical consolidated results of operations, financial position or cash flows. The recast financial information contained in Exhibit 99 does not represent a restatement of the Company’s previously issued financial statements. The information in this Item 8.01, including Exhibit 99, should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.


Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits. The following exhibits are filed with this document:
        
Exhibit Number
Description
104
Cover Page Interactive Data File (embedded within the Inline eXtensible Business Reporting Language (Inline XBRL) document)
2



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.                            

                                               >                 
COLGATE-PALMOLIVE COMPANY
Date: March 17, 2026
By:
 /s/ Stanley J. Sutula III    
Name: Stanley J. Sutula III
Title: Chief Financial Officer



3

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Colgate Palmolive Co (CL)

Reference

Frequently asked questions

When did Colgate Palmolive Co file this 8-K?
Colgate Palmolive Co (CL) filed this Current Report (Form 8-K) with the SEC on March 17, 2026. The accession number assigned by EDGAR is 0000021665-26-000010.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Colgate realigns segments to form Europe, Middle East and Africa; Russia/Belarus moved to Asia Pacific; historical data recast. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Colgate Palmolive Co's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Colgate Palmolive Co has filed under CIK 21665, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer